Phase II study with mitomycin, ifosfamide and carboplatin in inoperable non-small cell lung cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/107854
Title:
Phase II study with mitomycin, ifosfamide and carboplatin in inoperable non-small cell lung cancer.
Authors:
Von Rohr, A; Anderson, Heather; McIntosh, R; Thatcher, Nick
Abstract:
In a phase II study of non-small cell lung cancer a new chemotherapy combination of mitomycin 6 mg/m2 intravenously on day 1, carboplatin 400 mg/m2 intravenously on day 1 and ifosfamide with mesna 5 g/m2 intravenously over 24 hours on day 1 was evaluated. A maximum of four chemotherapy cycles was given at intervals of 4 weeks to 34 patients with progressive, inoperable disease. 1 complete and 10 partial remissions were documented, the overall response rate being 32.4%. In a further 13 patients (38.2%) the previously progressing tumours remained stable for at least 6 weeks. The median time to progression for responding patients was 184 days. The median survival time for the whole group has not yet been reached at 293 days. A considerable but easily manageable myelosuppression was the principal toxicity despite a "no dose reduction" policy. Indeed, the dose intensity of the chemotherapy actually given was extremely close (97%) to that intended on protocol. In conclusion, the regimen is active in patients with advanced non-small cell lung cancer but requires regular haematological monitoring to prevent morbidity resulting from myelotoxicity.
Affiliation:
CRC Department of Medical Oncology, Christie Hospital & Holt Radium Institute, Manchester, U.K.
Citation:
Phase II study with mitomycin, ifosfamide and carboplatin in inoperable non-small cell lung cancer. 1991, 27 (9):1106-8 Eur. J. Cancer
Journal:
European Journal of Cancer
Issue Date:
1991
URI:
http://hdl.handle.net/10541/107854
DOI:
10.1016/0277-5379(91)90303-U
PubMed ID:
1659850
Type:
Article
Language:
en
ISSN:
0959-8049
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorVon Rohr, Aen
dc.contributor.authorAnderson, Heatheren
dc.contributor.authorMcIntosh, Ren
dc.contributor.authorThatcher, Nicken
dc.date.accessioned2010-07-17T10:19:11Z-
dc.date.available2010-07-17T10:19:11Z-
dc.date.issued1991-
dc.identifier.citationPhase II study with mitomycin, ifosfamide and carboplatin in inoperable non-small cell lung cancer. 1991, 27 (9):1106-8 Eur. J. Canceren
dc.identifier.issn0959-8049-
dc.identifier.pmid1659850-
dc.identifier.doi10.1016/0277-5379(91)90303-U-
dc.identifier.urihttp://hdl.handle.net/10541/107854-
dc.description.abstractIn a phase II study of non-small cell lung cancer a new chemotherapy combination of mitomycin 6 mg/m2 intravenously on day 1, carboplatin 400 mg/m2 intravenously on day 1 and ifosfamide with mesna 5 g/m2 intravenously over 24 hours on day 1 was evaluated. A maximum of four chemotherapy cycles was given at intervals of 4 weeks to 34 patients with progressive, inoperable disease. 1 complete and 10 partial remissions were documented, the overall response rate being 32.4%. In a further 13 patients (38.2%) the previously progressing tumours remained stable for at least 6 weeks. The median time to progression for responding patients was 184 days. The median survival time for the whole group has not yet been reached at 293 days. A considerable but easily manageable myelosuppression was the principal toxicity despite a "no dose reduction" policy. Indeed, the dose intensity of the chemotherapy actually given was extremely close (97%) to that intended on protocol. In conclusion, the regimen is active in patients with advanced non-small cell lung cancer but requires regular haematological monitoring to prevent morbidity resulting from myelotoxicity.en
dc.language.isoenen
dc.subjectHaematologic Diseasesen
dc.subjectLung Canceren
dc.subject.meshAged-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshCarboplatin-
dc.subject.meshCarcinoma, Non-Small-Cell Lung-
dc.subject.meshDrug Evaluation-
dc.subject.meshFemale-
dc.subject.meshHematologic Diseases-
dc.subject.meshHumans-
dc.subject.meshIfosfamide-
dc.subject.meshLung Neoplasms-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshMitomycins-
dc.subject.meshPrognosis-
dc.subject.meshTime Factors-
dc.titlePhase II study with mitomycin, ifosfamide and carboplatin in inoperable non-small cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, Christie Hospital & Holt Radium Institute, Manchester, U.K.en
dc.identifier.journalEuropean Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.